Sterling Pharma Solutions has invested in a center of excellence for research into commercial applications of continuous flow chemistry at its site in Dudley, UK.
Sterling Pharma Solutions, a global contract development and manufacturing organization, has completed the initial phase of investment to create a center of excellence for research into commercial applications of continuous flow chemistry at its site in Dudley, United Kingdom.
The investment, which was announced in a Sept. 8, 2021 press release, follows on from the appointment of Professor Ian R. Baxendale as a team leader for a group of chemists and engineers that are dedicated to continuous flow chemistry. A focus for the team will be on the rapid and successful development of processes to kilogram scale initially with a view to future industrialization. The installation of multiple flow chemistry platforms into a research laboratory at the Dudley site has been completed to allow for the investigation of a wide range of chemical processes.
“Flow chemistry has the potential to open up applications within commercial pharmaceutical manufacturing that are currently used only within research and development or academic applications,” commented Mark Muldowney, head of technology and innovation at Sterling, in the press release. “We are seeing significant interest in continuous flow development and production from customers and our goal is to provide scale-up expertise to leverage the benefits this technology has to offer in terms of efficiency, safety, and economics.”
Source: Sterling
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.